These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33810898)

  • 1. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys.
    Peyvandi F; Garagiola I; Mannucci PM
    Blood Rev; 2021 Sep; 49():100828. PubMed ID: 33810898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions of analgesic medicines: analysis of the Romanian pharmacovigilance database.
    Cazacu I; Stroe R; Dondera R; Mogosan C; Haramburu F; Fourrier-Réglat A; Loghin F
    Fundam Clin Pharmacol; 2018 Jun; 32(3):330-336. PubMed ID: 29314262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU's new pharmacovigilance legislation: considerations for biosimilars.
    Calvo B; Zuñiga L
    Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011.
    Aagaard L; Hansen EH
    BMC Pharmacol Toxicol; 2013 Jun; 14():30. PubMed ID: 23763896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
    Lam S
    Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database.
    Konstantinov K; Dolladille C; Gillet B; Alexandre J; Aouba A; Deshayes S; Repesse Y
    Haemophilia; 2023 Jan; 29(1):186-192. PubMed ID: 36367755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
    Aagaard L; Hansen EH
    Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in pharmaceutical companies: An overview.
    Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
    van Hunsel F; de Waal S; Härmark L
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
    Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
    Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety data and withdrawal of hepatotoxic drugs.
    Babai S; Auclert L; Le-Louët H
    Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
    Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
    Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.